Please login to the form below

Not currently logged in
Email:
Password:

talimogene laherparepvec

This page shows the latest talimogene laherparepvec news and features for those working in and with pharma, biotech and healthcare.

Transgene slumps as viral cancer therapy fails phase 3 trial

Transgene slumps as viral cancer therapy fails phase 3 trial

It’s an approach that has already yielded one FDA- and EMA-approved product – Amgen’s Imlygic (talimogene laherparepvec) – which was launched in 2015 for melanoma but hasn’t made much

Latest news

More from news
Approximately 4 fully matching, plus 19 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Oncolytic viruses. An oncolytic virus is a virus that preferentially infects and kills cancer cells, and to date a handful of therapies – Amgen’s Imlygic (talimogene laherparepvec) in the US and

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

Using human insights to push healthcare communications forward
This blog highlights the value of human perspectives, showing how insights can propel healthcare communications forward to ultimately improve lives...
RWE Blog 4: The place of real-world evidence in the market access strategy
The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in...
RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...

Infographics